MedTrace Logo

A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression

NCT01774045 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-08-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive effect.

Conditions

Interventions

DRUG

PDC-1421

DRUG

Placebo

Sponsors & Collaborators

  • BioLite, Inc.

    lead INDUSTRY

Principal Investigators

  • Cheng-Ta Li, MD · Taipei Veterans General Hospital, Taiwan

  • Tung-Ping Su, M.D · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01774045 on ClinicalTrials.gov